Brief: Helix Biopharma announces FDA approval to accelerate dose escalation for U.S. Phase I clinical study

Helix Biopharma

27/09/2017 22:09

Sept 27 (Reuters) - Helix Biopharma Corp  HBP.TO  
    * Helix Biopharma Corp. Announces fda approval to accelerate 
dose escalation for U.S. Phase i clinical study 
    * Helix Biopharma Corp- U.S. Food and drug administration  
has approved an amendment to their U.S. Phase I study, protocol 
ldos001 
    * Helix Biopharma - study to implement accelerated dose 
design up to 6g/kg followed by standard 3+3 design for final 2 
dosing cohorts, 9 and 12 g/kg 
 
Source text for Eikon:  ID:nCCNG75JHa  
Further company coverage:  HBP.TO  
 
 (((Bangalore.newsroom@thomsonreuters.com;);))